The Risk of the Development and Relationship of Kidney Stone Disease and Osteoporosis (Literature review)
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Urinary stone disease (USD) is a common pathology with the formation of calculi in the kidneys, ureter, and bladder. Besides the family history, hyperparathyroidism, hypo- and hypervitaminosis of vitamin D, hypercalciuria, and hyperoxaluria are the high risk factors for USD development. This is due primarily to the activation of bone resorption with increased hypercalciuria. It is known that in the urine of every person there is a small amount of urea, inorganic salts, uric acid, creatinine and other substances. The main reason for the formation of calculi is a certain metabolic disorder, which leads to the formation of insoluble salts from which stones are formed – urates, phosphates, oxalates, etc.
One of the unsolved problems in the metaphylaxis of USD is the treatment and prevention of osteoporosis which is comorbid with it, since calcium and vitamin D preparations are widely used for the prevention and treatment of osteoporosis. Osteoporosis and arterial calcification often coincide in the nature of the manifestation, which indicates an imbalance in the redistribution of calcium with a predominant direction in the vascular the wall.
Vitamin K2 deficiency is closely related to the process of vascular calcification. In the cardiovascular system, with the use of vitamin K antagonists or vitamin K deficiency, calcification of the endothelium of blood vessels occurs. The effect of osteocalcin protein on stone formation processes is controversial. For example, some researchers have found that high serum level of Glaprotein is associated with a lower risk of kidney stones.
Based on the results of a daily urinalysis study, the EAU Guidelines (2022) updated the recommendations on metaphylactic USD regarding the benefit/harm of additional calcium and vitamin D use in patients with nephrolithiasis depending on the type of crystalluria. The absence of recommendations for the management of patients with combined pathologies (USD, osteoporosis, cardiovascular diseases) prompts a comprehensive assessment of common risk factors, as well as the formation of programs and algorithms for early diagnosis and the development of recommendations for the prevention and avoidance of complications.
Based on the literature analysis, it was established that today the issue of choosing the optimal management for diagnosis and treatment of USD and osteoporosis is still very controversial and ambiguous. There is a necessity for detailed study of this problem, the development of a complex differentiated approach to diagnosis and treatment of patients.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
European Assosiation Urology. EUA Guidelines. Edn. presented at the EAU Annual Congress Amsterdam [Internet]. 2022 July 1-4; Amsterdam. Amsterdam: EAU; 2022. Available from: https://eaucongress.uroweb.org/info-centre/.
Katz JE, Soodana-Prakash N, Jain A, Parmar M, Smith N, Kryvenko O, et al. Influence of Age and Geography on Chemical Composition of 98043 Urinary Stones from the USA. Eur Urol Open Scie. 2021;34:19–26. doi: 10.1016/j.euros.2021.09.011.
GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study. Lancet (London, England). 2019;396(10258):1204–22. doi: 10.1016/S0140-6736(20)30925-9.
Lang J, Narendrula A, El-Zawahry A, Sindhwani P, Ekwenna O. Global Trends in Incidence and Burden of Urolithiasis from 1990 to 2019: An Analysis of Global Burden of Disease Study Data. Eur Urol Open Science. 2022;35:37–46. doi: 10.1016/j.euros.2021.10.008.
Ferraro PM, Curhan GC, D’Addessi A, Gambaro G. Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol. 2017;30(2):227. doi: 10.1007/s40620-016-0283-8.
Taguchi K, Hamamoto S, Okada A, Tanaka Y, Sugino T, Unno R, et al. Low bone mineral density is a potential risk factor for symptom onset and related with hypocitraturia in urolithiasis patients: a single‑center retrospective cohort study. BMC Urol. 2020;20(1):174. doi: 10.1186/s12894-020-00749-5.
Kordubailo I, Nikitin O, Nishkumay O, Samchuk P. Kidney stone diseases and osteoporosis – topic issues of comorbidity. Scie Med Youth J. 2021;127(4):38–43. doi: 0.32345/USMYJ.4(127).2021.
Rendina D, De Filippo G, Iannuzzo G, Abate V, Strazzullo P, Falchetti A. Idiopathic Osteoporosis and Nephrolithiasis: Two Sides of the Same Coin? Int J Mol Sci. 2020;21:81–3. doi: 10.3390/ijms21218183.
Baumann JM, Affolter B, Caprez U, Henze U. Calcium oxalate aggregation in whole urine, new aspects of calcium stone formation and metaphylaxis. European urology. 2003;43(4):421–5. doi: 10.1016/s0302-2838(03)00058-7.
Kanis J, Cooper C, Rizzoli R, Reginster J-Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44. doi: 10.1007/s00198-018-4704-5.
Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (Clinical research ed.). 2010;341:3691. doi: 10.1136/bmj.c3691.
Yasuda H. Discovery of the RANKL/RANK/OPG system. J Bone Mineral Metabol. 2021;39(1):2–11. doi: 10.1007/s00774-020-01175-1.
Biscetti F, Ferraro PM, Hiatt WR, Angelini F, Nardella E, Cecchini AL, et al. Inflammatory Cytokines Associated With Failure of Lower-Extremity Endovascular Revascularization (LER): A Prospective Study of a Population With Diabetes. Diabetes care. 2019;42(10):1939–45. doi: 10.2337/dc19-0408.
Garcia-Gomez MC, Vilahur G. Osteoporosis and vascular calcification: A shared scenario. Osteoporosis y calcificacion vascular: un escenario compartido. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad. Espanola de Arteriosclerosis. 2020;32(1):33–42. doi: 10.1016/j.arteri.2019.03.008.
Tang CY, Wu M, Zhao D, Edwards D, McVicar A, Luo Y, et al. Runx1 is a central regulator of osteogenesis for bone homeostasis by orchestrating BMP and WNT signaling pathways. PLoS genetics. 2021;17(1):e1009233. doi: 10.1371/journal.pgen.1009233.
Povoroznyuka VV, Hryhoryevoyi NV, Dyedukha NV. Vtorynnyy osteoporoz: monohrafiya. Kropyvnytskyy: Polium; 2021. 524 p.
Wen L, Chen J, Duan L, Li S. Vitamin K‑dependent proteins involved in bone and cardiovascular health (Review). Molecular medicine reports. 2018;18(1):3–15. doi: 10.3892/mmr.2018.8940.
De la Guía-Galipienso F, Martínez-Ferran M, Vallecillo N, Lavie CJ, Sanchis-Gomar F, Pareja-Galeano H. Vitamin D and cardiovascular health. Clinical nutrition (Edinburgh, Scotland). 2021;40(5):2946–57. doi: 10.1016/j.clnu.2020.12.025.
Heravi AS, Michos ED. Vitamin D and Calcium Supplements: Helpful, Harmful, or Neutral for Cardiovascular Risk? Methodist DeBakey Cardiovasc J. 2019;15(3):207–13. doi: 10.14797/mdcj-15-3-207.
Penniston KL. Diet and Kidney Stones: The Ideal Questionnaire. Eur Urol Focus. 2021;7(1):9–12. doi: 10.1016/j.euf.2020.09.001.
Letavernier E, Daudon M. Vitamin D, Hypercalciuria and Kidney Stones. Nutr. 2018;10(3):366. doi: 10.3390/nu10030366.
Ferraro PM, Bargagli M. Dietetic and lifestyle recommendations for stone formers. Consejos dieteticos y de estilo de vida en pacientes con litiasis urinarias. Arch Espanoles de Urol. 2021;74(1):112–22.
Van der Burgh AC, Oliai Araghi S, Zillikens MC, Koromani F, Rivadeneira F, Van der Velde N, et al. The impact of thiazide diuretics on bone mineral density and the trabecular bone score: the Rotterdam Study. Bone. 2020;138:115475. doi: 10.1016/j.bone.2020.115475.
Al Ghorani H, Kulenthiran S, Lauder L, Böhm M, Mahfoud F. Hypertension trials update. J Hum Hypertension. 2021;35(5):398–409. doi: 10.1038/s41371-020-00477-1.
Tang KS, Medeiros ED, Shah AD. Wide pulse pressure: A clinical review. J Clin Hyper (Greenwich, Conn). 2020;22(11):1960–7. doi: 10.1111/jch.14051.
Finlayson B. Physicochemical aspects of urolithiasis. Kidney International. 1978;13(5):344–60. doi: 10.1038/ki.1978.53.
Baumann JM. Physico-chemical aspects of calcium stone formation. Urol Res. 1990;18(1):25–30. doi: 10.1007/BF00301524.
Asselman M, Verkoelen CF. Crystalcell interaction in the pathogenesis of kidney stone disease. Current Opinion in Urol. 2002;12(4):271–6. doi: 10.1097/00042307-200207000-00002.
Ganesan C, Thomas IC, Romero R, Song S, Conti S, Elliott C, et al. Osteoporosis, Fractures, and Bone Mineral Density Screening in Veterans With Kidney Stone Disease. J Miner Res. 2021;36(5):872–8. doi: 10.1002/jbmr.4260.
Millera K, Stenzlb A, Tombalc B. Advances in the Therapy of Prostate Cancer-Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL. Eur Urol Supplements. 2009;8(9):747–52. doi: 10.1016/j.eursup.2009.07.001.
Christoph F, König F, Lebentrau S, Jandrig B, Krause H, Strenziok R, et al. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease. World J Urol. 2018;36(2):187–92. doi: 10.1007/s00345-017-2145-y.
Jakob A, Zahn MO, Nusch A, Werner T, Schnell R, Frank M, et al. Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study. J Bone Oncol. 2022;33:100420. doi: 10.1016/j.jbo.2022.100420.
Katz JE, Soodana-Prakash N, Jain A, Parmar M, Smith N, Kryvenko O, et al. Influence of Age and Geography on Chemical Composition of 98043 Urinary Stones from the USA. Eur Urol Open Science. 2021;34:19–26. doi: 10.1016/j.euros.2021.09.011.
GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England). 2020;396(10258):1204–22. doi: 10.1016/S0140-6736(20)30925-9.
Lang J, Narendrula A, El-Zawahry A, Sindhwani P, Ekwenna O. Global Trends in Incidence and Burden of Urolithiasis from 1990 to 2019: An Analysis of Global Burden of Disease Study Data. Eur Urol Open Sci. 2022;35:37–46. doi: 10.1016/j.euros.2021.10.008.
Reinhold S, Blankesteijn WM, Foulquier S. The Interplay of WNT and PPARγ Signaling in Vascular Calcification. Cells. 2020;9(12):2658. doi: 10.3390/cells9122658.
Khan SR, Canales BK, Dominguez-Gutierrez PR. Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation. Natur Rev Nephrol. 2021;17(6):417–33. doi: 10.1038/s41581-020-00392-1.
Wang Z, Zhang Y, Zhang J, Deng Q, Liang H. Recent advances on the mechanisms of kidney stone formation (Revie). Int J Mol Med. 2021;48(2):149. doi: 10.3892/ijmm.2021.4982.
Ketha H, Singh RJ, Grebe SK, Bergstralh EJ, Rule AD, Lieske JC, Kumar R. Altered Calcium and Vitamin D Homeostasis in First-Time Calcium Kidney Stone-Formers. PloS One. 2015;10(9):e0137350. doi: 10.1371/journal.pone.0137350.
Wu J, Tao Z, Deng Y, Liu Q, Liu Y, Guan X, et al. Calcifying nanoparticles induce cytotoxicity mediated by ROSJNK signaling pathways. Urolithiasis. 2019;47(2):125–35. doi: 10.1007/s00240-018-1048-8.
Castiglione V, Pottel H, Lieske JC, Lukas P, Cavalier E, Delanaye P, et al. Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones. J Nephrol. 2020;33(1):101–7. doi: 10.1007/s40620-019-00623-0.
